Empagliflozin for Prevention of Acute Kidney Injury in Patients With Type 2 Diabetes Mellitus Undergoing Extracorporeal On-pump CABG: The POST-CABGDM Trial
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Empagliflozin (Primary)
- Indications Acute kidney injury; Coronary artery disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms POST-CABGDM
- 07 Jun 2024 Status changed from recruiting to completed.
- 18 Oct 2023 Planned number of patients changed from 144 to 155.
- 18 Oct 2023 Planned End Date changed from 30 Nov 2023 to 28 Feb 2024.